Javascript must be enabled to continue!
Lung uptake on I-131 therapy and short-term outcome in patients with lung metastasis from differentiated thyroid cancer
View through CrossRef
Abstract
Objective
It is sometimes difficult to assess I-131 lung uptake at the initial I-131 therapy because of strong artifacts from I-131 uptake in the thyroid bed. The aim of this study was to analyze the lung uptake at the second I-131 therapy for lung metastasis in patients who did not have lung uptake at the initial therapy from differentiated thyroid carcinoma (DTC). Then, we also analyzed the relationship between the initial lung uptake and short-term outcome after I-131 therapies.
Methods
This study included 62 DTC patients with lung metastasis. The patients were classified into 2 groups according to the lung uptake at the initial I-131 therapy such as patients with lung uptake (positive uptake group n = 31) and those without lung uptake (negative uptake group n = 31). The lung uptake was analyzed at the second therapy in both groups. The short-term outcome was also analyzed based on the CT findings of lung metastasis size and serum thyroglobulin level between the two groups.
Results
The positive uptake group showed positive lung uptake at the second therapy in 23 patients (74 %), whereas none of negative uptake group showed any lung uptake at the second therapy (P < 0.01). The positive uptake group significantly decreased in the size of lung metastasis from the initial therapy to the second therapy (20.0 ± 11.7 to 16.6 ± 9.6 mm, P < 0.01) with further decrease after the second therapy (P < 0.05). The serum thyroglobulin level was also significantly decreased from the initial therapy to the second therapy (4348 ± 7011 to 2931 ± 4484 ng/ml, P < 0.05). In contrast, the negative uptake group significantly increased in the size of lung metastasis from the initial therapy to the second therapy (17.3 ± 12.2 to 19.9 ± 14.3 mm, P < 0.01) with further increase after the second therapy (P < 0.01).
Conclusion
No patients without lung uptake at the initial I-131 therapy showed lung uptake at the second therapy, or showed treatment effect. Therefore, second I-131 therapy for these patients with initially negative lung uptake should be considered cautiously.
Springer Science and Business Media LLC
Title: Lung uptake on I-131 therapy and short-term outcome in patients with lung metastasis from differentiated thyroid cancer
Description:
Abstract
Objective
It is sometimes difficult to assess I-131 lung uptake at the initial I-131 therapy because of strong artifacts from I-131 uptake in the thyroid bed.
The aim of this study was to analyze the lung uptake at the second I-131 therapy for lung metastasis in patients who did not have lung uptake at the initial therapy from differentiated thyroid carcinoma (DTC).
Then, we also analyzed the relationship between the initial lung uptake and short-term outcome after I-131 therapies.
Methods
This study included 62 DTC patients with lung metastasis.
The patients were classified into 2 groups according to the lung uptake at the initial I-131 therapy such as patients with lung uptake (positive uptake group n = 31) and those without lung uptake (negative uptake group n = 31).
The lung uptake was analyzed at the second therapy in both groups.
The short-term outcome was also analyzed based on the CT findings of lung metastasis size and serum thyroglobulin level between the two groups.
Results
The positive uptake group showed positive lung uptake at the second therapy in 23 patients (74 %), whereas none of negative uptake group showed any lung uptake at the second therapy (P < 0.
01).
The positive uptake group significantly decreased in the size of lung metastasis from the initial therapy to the second therapy (20.
0 ± 11.
7 to 16.
6 ± 9.
6 mm, P < 0.
01) with further decrease after the second therapy (P < 0.
05).
The serum thyroglobulin level was also significantly decreased from the initial therapy to the second therapy (4348 ± 7011 to 2931 ± 4484 ng/ml, P < 0.
05).
In contrast, the negative uptake group significantly increased in the size of lung metastasis from the initial therapy to the second therapy (17.
3 ± 12.
2 to 19.
9 ± 14.
3 mm, P < 0.
01) with further increase after the second therapy (P < 0.
01).
Conclusion
No patients without lung uptake at the initial I-131 therapy showed lung uptake at the second therapy, or showed treatment effect.
Therefore, second I-131 therapy for these patients with initially negative lung uptake should be considered cautiously.
Related Results
Primary Thyroid Non-Hodgkin B-Cell Lymphoma: A Case Series
Primary Thyroid Non-Hodgkin B-Cell Lymphoma: A Case Series
Abstract
Introduction
Non-Hodgkin lymphoma (NHL) of the thyroid, a rare malignancy linked to autoimmune disorders, is poorly understood in terms of its pathogenesis and treatment o...
Clinicopathological Features of Indeterminate Thyroid Nodules: A Single-center Cross-sectional Study
Clinicopathological Features of Indeterminate Thyroid Nodules: A Single-center Cross-sectional Study
Abstract
Introduction
Due to indeterminate cytology, Bethesda III is the most controversial category within the Bethesda System for Reporting Thyroid Cytopathology. This study exam...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
The effect of miRNAs and MALAT1 related with the prognosis of Her-2 positive breast cancer patients with lymph node metastasis
The effect of miRNAs and MALAT1 related with the prognosis of Her-2 positive breast cancer patients with lymph node metastasis
Abstract
Background: To analyze and screen the miRNAs associated with lymph node metastasis of breast cancer (BC), and to explore the roles of these miRNAs in the prolifera...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
Kikuchi-Fujimoto Disease Coexistent with Papillary Thyroid Carcinoma: A Report of Two Cases
Kikuchi-Fujimoto Disease Coexistent with Papillary Thyroid Carcinoma: A Report of Two Cases
Abstract
Introduction
Kikuchi-Fujimoto Disease (KFD), characterized by histiocytic necrotizing lymphadenitis, is a rare condition of unknown etiology. Diagnosis is dependent on lym...
Relationship between serum NDRG3 and papillary thyroid carcinoma
Relationship between serum NDRG3 and papillary thyroid carcinoma
BackgroundIn recent years, papillary thyroid carcinoma is considered to be one of the fastest increaseing cancer. NDRG family member 3 (NDRG3) has been proposed as a molecular mark...
Neoplasms of the Thyroid
Neoplasms of the Thyroid
Overview
Thyroid cancer is the most common malignancy of a classical endocrine organ. The most common forms of thyroid cancer derive from follicular thyroid cells, are ch...


